- home
- R&D
- Clinical Trial
Innovative Drug
| Product/Project Name | Target Indication | Title | Stage | ClinicalTrials.gov Identifier: |
|---|---|---|---|---|
| S-217622 | Covid-19 | A Phase 2/3 Study of S-217622 in Participants Infected with SARS-CoV-2 | Phase 2/3 | - |
| IDG-16177 | Type 2 DM | A Placebo- and Active-controlled, Randomised, Double-blind, Dose-escalation Phase I Study of IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics With the Exploration on Its Pharmacodynamics and Efficacy | Phase 1 | NCT04982705 |
| ID119031166 | NASH | A Placebo-controlled, Randomized, Double-blind, Single and Multiple Dose-escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects in Healthy Participants | Phase 1 | NCT05604287 |
| Besivo | Hepatitis B | A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks | Phase 3 | NCT01937806 |
| Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver | Phase 4 | NCT03604016 | ||
| A Randomized, Open-Label, Parallel, Multi-Center, Non-inferiority, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Switching to Besifovir Dipivoxil Maleate From Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients Who Pretreated With TDF | Phase 4 | NCT04202536 | ||
| ID120040002 | GERD | A Randomized, Double-blinded, Partial-open, Placebo and Active-controlled, Single and Multiple Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ID120040002 in Healthy Volunteers | Phase 1 | NCT05663879 |
